ANALIZE MEDICALE DE LABORATOR
Aici gasiti analizele medicale grupate pe categorii precum si detalii generale si specifice pentru categoriile respective.
Selectati o categorie din lista de mai jos:
Solutie antistress!
Construieste poduri :)
Prinde pisica neagra :)
Isolagen Inc. Completes Injections Of Isolagen Therapy(TM) In Phase III Wrinkle And Phase II Full Face Studies
Isolagen(TM), Inc. (Amex:
ILE) announced that injections have been completed in the pivotal
Phase III multi-center, double-blind, randomized, placebo-controlled
clinical trials evaluating the Isolagen Therapy(TM) for the treatment of
nasolabial folds, or wrinkles (Studies IT-A-005 and IT-A-006). Subjects
have advanced to the follow-up period of the study.
Isolagen also announced the completion of injections in the Phase II
open label study designed to gather further safety and potential
application information on the use of the Isolagen Therapy(TM) for the full
face (Study IT-A-007). The subjects in this study also have advanced to the
follow-up period.
"These are important clinical milestones to Isolagen, especially the
advancement of our lead Phase III pivotal wrinkle study to the follow-up
period of the trial," said Declan Daly, Chief Executive Officer of
Isolagen, Inc.
About Isolagen, Inc.
Isolagen(TM), Inc. (AMEX: ILE) is an aesthetic and therapeutic company
committed to developing and commercializing scientific advances and
innovative technologies. The company's technology platform includes the
Isolagen Process(TM), a cell processing system for skin and tissue
rejuvenation which is currently in clinical development for a broad range
of aesthetic and therapeutic applications including wrinkles, acne scars,
burns and periodontal disease. Isolagen also commercializes a
scientifically-advanced line of skincare systems through its majority-owned
subsidiary, Agera(R) Laboratories, Inc. For additional information, please
visit http://www.isolagen.com.
Isolagen Forward Looking Statements
All statements in this news release that are not based on historical
fact are "forward-looking statements" within the meaning of the Private
Securities Litigation Reform Act of 1995 and the provisions of Section 27A
of the Securities Act of 1933, as amended, and Section 21E of the
Securities Exchange Act of 1934, as amended. While management has based any
forward-looking statements contained herein on its current expectations,
the information on which such expectations were based may change. These
forward-looking statements rely on a number of assumptions concerning
future events and are subject to a number of risks, uncertainties, and
other factors, many of which are outside of our control, that could cause
actual results to materially differ from such statements. Such risks,
uncertainties, and other factors include, but are not necessarily limited
to, those set forth under Item 1A "Risk Factors" in the Company's Annual
Report on Form 10-K for the year ended December 31, 2006, as updated in
"Item 1A. Risk Factors" in the Company's Quarterly Reports on Form 10-Q. We
operate in a highly competitive and rapidly changing environment, thus new
or unforeseen risks may arise. Accordingly, investors should not place any
reliance on forward-looking statements as a prediction of actual results.
We disclaim any intention to, and undertake no obligation to, update or
revise any forward-looking statements. Readers are also urged to carefully
review and consider the other various disclosures in the Company's Annual
Report on Form 10-K for the year ended December 31, 2006, as well as other
public filings with the SEC since such date.
Isolagen, Inc.
http://www.isolagen.com
Isolagen Inc completeaza preparate injectabile Din Isolagen Terapia (TM) În faza a III Wrinkle ªi, faza a II-nominalã totalã de Studii - Isolagen Inc. Completes Injections Of Isolagen Therapy(TM) In Phase III Wrinkle And Phase II Full Face Studies - articole medicale engleza - startsanatate